Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Clinical Trials

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Overview Studies Clinical Trials
Active Not Recruiting PHASE1 INTERVENTIONAL NCT06403761

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.

Interventions

Name: Semaglutide
Type: DRUG
Description: Participants will receive once-weekly semaglutide subcutaneously.
Name: Cagrilintide
Type: DRUG
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Name: Placebo semaglutide
Type: DRUG
Description: Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
Name: Placebo cagrilintide
Type: DRUG
Description: Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Primary Outcomes

Measure: To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC)
TimeFrame: Baseline to week 28
Description: M-value from the HEC is calculated from glucose infusion rate (GIR) over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[milligram per minute per kilogram {mg/min/kg}\]). Measured in mg/min/kg.

Trial Information

NCT ID

NCT06403761

Status

Active Not Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025